Brent Ursel, PA
Physician Assistant · Seward, AKNPI 1679637011
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 24.6% of the total. Reporting peaked in 2021 at $588 and has fallen 72.6% since, to $161 in 2025.
Across 81 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$396
- AstraZeneca$274
- Lilly USA, LLC$185
- Pfizer$182
- Novartis$121
- Novo Nordisk$103
- plus $345 from 11 others
What the payments were for
- Food & beverage$1,608100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $396 |
| AstraZeneca | 15 | $274 |
| Lilly USA, LLC | 10 | $185 |
| Pfizer | 10 | $182 |
| Novartis | 5 | $121 |
| Novo Nordisk | 5 | $103 |
| Amgen | 5 | $92 |
| Upsher-smith Laboratories LLC | 3 | $46 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Johnson & Johnson | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$1,608 in reported general payments places this provider in the 85th percentile of 365 physician assistant providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $30,964 |
| MounjaroTirzepatide | 25 | $25,229 |
| EliquisApixaban | 16 | $24,101 |
| Nurtec OdtRimegepant Sulfate | 23 | $22,056 |
| TrulicityDulaglutide | 14 | $20,204 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $15,866 |
| OxycontinOxycodone Hcl | 22 | $15,312 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,101 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,453 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 239 | $7,283 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,826 |
| Tamsulosin Hcl | 100 | $2,245 |
| Dutasteride | 29 | $2,027 |
| SynthroidLevothyroxine Sodium | 17 | $1,694 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $182 | $46,15739 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $185 | $45,96360 claims |
| Novo NordiskOzempic | $103 | $30,96429 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $274 | $15,55434 claims |
| AbbVieSynthroid | $396 | $1,69417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 365 physician assistant providers in Alaska.
Other physician assistant in Seward
- Jeremy RosieckiAnchorage$93K
- Ivy ParayoAnchorage$12K
- Shannon DieffenderferAnchorage$11K
- Zach ZipsirAnchorage$8K
- James LafleurFairbanks$8K
- Tara WoodAnchorage$8K
- Jared WallaceKenai$7K
- Madison RosinAnchorage$7K
- Pamela TittleAnchorage$7K
- Pamela HaughomAnchorage$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.